Epsilon M&A Deal Report - Syncrosome

Transaction Multiples for the Valuation of Private Companies

Etap > Syncrosome

Announced Date : 10 October 2023

Type : Acquisition of Majority Stake

Deal Value : Yes

Acquirer : Etap

Target: Syncrosome

Target Country: France

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> Founded in 2000, Syncrosome is a CRO (Contract Research Organizations) specialising in preclini ...

No EMAT : 120415

Transaction multiples available

	EV/Sales	EV/Gross Profit	EV/EBITDA	EV/EBIT	Eq/PBT	P/E	Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating ***

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1234

Example of comparable transactions on EMAT (same sub-sector):

Date	Acquirer	Target	Country	Multiples	See details
23/12/2024	Private Group led by Andera Acto	Centre Azuréen de Cancérologie (CAC)	France	*
04/02/2025	Fagron	Guinama	Spain	**

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Subscribe to EMAT database